NewAmsterdam Pharma (NASDAQ:NAMS) Receives “Sell (D-)” Rating from Weiss Ratings

NewAmsterdam Pharma (NASDAQ:NAMS)‘s stock had its “sell (d-)” rating restated by analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Other analysts have also issued reports about the company. Royal Bank Of Canada lifted their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 5th. Citigroup boosted their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright began coverage on NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a “neutral” rating and a $27.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

NewAmsterdam Pharma Stock Down 1.5%

NAMS stock opened at $35.72 on Friday. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $41.47. The stock’s 50 day moving average is $28.94 and its 200-day moving average is $22.94. The firm has a market capitalization of $4.02 billion, a PE ratio of -22.05 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. On average, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,260 shares of the stock in a transaction on Monday, September 8th. The stock was acquired at an average price of $24.99 per share, with a total value of $31,487.40. Following the transaction, the director directly owned 3,027,864 shares of the company’s stock, valued at approximately $75,666,321.36. This trade represents a 0.04% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total value of $3,874,500.00. Following the transaction, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at $387,450. The trade was a 90.91% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders purchased 2,391 shares of company stock valued at $58,424 and sold 226,342 shares valued at $5,748,019. 20.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. Mather Group LLC. purchased a new stake in NewAmsterdam Pharma during the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in NewAmsterdam Pharma in the third quarter worth about $30,000. Quarry LP bought a new stake in NewAmsterdam Pharma in the first quarter worth about $25,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock valued at $80,000 after purchasing an additional 596 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock worth $123,000 after buying an additional 3,390 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.